

THE LANCET

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Salman R A-S, Beller E, Kagan J, et al. Increasing value and reducing waste in biomedical research regulation and management. *Lancet* 2014; published online Jan 8. [http://dx.doi.org/10.1016/S0140-6736\(13\)62297-7](http://dx.doi.org/10.1016/S0140-6736(13)62297-7).

WEB EXTRA MATERIAL: FURTHER READING

Introduction

- w1. Warlow C. Over-regulation of clinical research: a threat to public health. *Clin Med* 2005; 5(1):33-38.
- w2. Stewart PM, Stears A, Tomlinson JW, Brown MJ. Regulation-the real threat to clinical research. *BMJ* 2008; 337:a1732.
- w3. Yusuf S. Damage to important clinical trials by over-regulation. *Clin Trials* 2010; 7(6):622-625.
- w4. Fost N, Levine RJ. The dysregulation of human subjects research. *JAMA* 2007; 298(18):2196-2198.

Regulation can be complicit with other sources of waste and inefficiency

- w5. Sena E, van der Worp HB, Howells D, Macleod M. How can we improve the pre-clinical development of drugs for stroke? *Trends Neurosci* 2007; 30(9):433-439.
- w6. Vesterinen HM, Sena ES, French-Constant C, Williams A, Chandran S, Macleod MR. Improving the translational hit of experimental treatments in multiple sclerosis. *Mult Scler* 2010; 16(9):1044-1055.
- w7. Rooke ED, Vesterinen HM, Sena ES, Egan KJ, Macleod MR. Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysis. *Parkinsonism Relat Disord* 2011; 17(5):313-320.

Regulation of clinical biomedical research

Burden and inconsistencies in regulation

- w8. Ness RB. Influence of the HIPAA Privacy Rule on health research. *JAMA* 2007; 298(18):2164-2170.
- w9. Vajdic CM, Meagher NS, Hicks SC, Faedo M, Ward RL, Pearson SA. Governance approval for multisite, non-interventional research: what can Harmonisation of Multi-Centre Ethical Review learn from the New South Wales experience? *Intern Med J* 2012; 42(2):127-131.
- w10. Petersen LA, Simpson K, Sorelle R, Urech T, Chitwood SS. How variability in the institutional review board review process affects minimal-risk multisite health services research. *Ann Intern Med* 2012; 156(10):728-735.
- w11. Dattani N, Hardelid P, Davey J, Gilbert R. Accessing electronic administrative health data for research takes time. *Arch Dis Child* 2013; 98(5):391-392.
- w12. Haynes R, Bowman L, Rahimi K, Armitage J. How the NHS research governance procedures could be modified to greatly strengthen clinical research. *Clin Med* 2010; 10(2):127-129.
- w13. Wang-Gillam A, Williams K, Novello S, Gao F, Scagliotti GV, Govindan R. Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic. *J Clin Oncol* 2010; 28(24):3803-3807.
- w14. Lambers Heerspink HJ, Dobre D, Hillege HL, Grobbee DE, de ZD. Does the European clinical trials directive really improve clinical trial approval time? *Br J Clin Pharmacol* 2008; 66(4):546-550.
- w15. Schnitzbauer AA, Lamby PE, Mutzbauer I, Zuelke C, Schlitt HJ, Geissler EK. Procedures for ethical review for clinical trials within the EU. *BMJ* 2009; 338:b1893.
- w16. Veerus P, Lexchin J, Hemminki E. Legislative regulation and ethical governance of medical research in different European Union countries. *J Med Ethics* 2013.
- w17. Hearnshaw H. Comparison of requirements of research ethics committees in 11 European countries for a non-invasive interventional study. *BMJ* 2004; 328(7432):140-141.
- w18. Aban IB, Wolfe GI, Cutter GR, Kaminski HJ, Jaretzki A, III, Minisman G et al. The MGTX experience: challenges in planning and executing an international, multicenter clinical trial. *J Neuroimmunol* 2008; 201-202:80-84.
- w19. Dilts DM, Sandler AB, Cheng SK, Crites JS, Ferranti LB, Wu AY et al. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. *J Clin Oncol* 2009; 27(11):1761-1766.
- w20. Dilts DM, Sandler A, Cheng S, Crites J, Ferranti L, Wu A et al. Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group. *Clin Cancer Res* 2008; 14(11):3427-3433.
- w21. Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. *J Clin Oncol* 2006; 24(28):4545-4552.
- w22. Al-Shahi Salman R, Brock TM, Dennis MS, Sandercock PA, White PM, Warlow C. Research governance impediments to clinical trials: a retrospective survey. *J R Soc Med* 2007; 100(2):101-104.
- w23. Laken MA, Dawson R, Engelman O, Lovelace O, Way C, Egan BM. Comparative effectiveness research in the "real" world: lessons learned in a study of treatment-resistant hypertension. *J Am Soc Hypertens* 2013; 7(1):95-101.

- w24. Ravina B, Deuel L, Siderowf A, Dorsey ER. Local institutional review board (IRB) review of a multicenter trial: local costs without local context. *Ann Neurol* 2010; 67(2):258-260.
- w25. Wagner TH, Murray C, Goldberg J, Adler JM, Abrams J. Costs and benefits of the national cancer institute central institutional review board. *J Clin Oncol* 2010; 28(4):662-666.
- w26. Menikoff J. The paradoxical problem with multiple-IRB review. *N Engl J Med* 2010; 363(17):1591-1593.
- w27. Millum J, Menikoff J. Streamlining ethical review. *Ann Intern Med* 2010; 153(10):655-657.
- w28. Flynn KE, Hahn CL, Kramer JM, Check DK, Dombeck CB, Bang S et al. Using Central IRBs for Multicenter Clinical Trials in the United States. *PLoS ONE* 2013; 8(1):e54999.
- w29. Redshaw ME, Harris A, Baum JD. Research ethics committee audit: differences between committees. *J Med Ethics* 1996; 22(2):78-82.
- w30. Willison DJ, Emerson C, Szala-Meneok KV, Gibson E, Schwartz L, Weisbaum KM et al. Access to medical records for research purposes: varying perceptions across research ethics boards. *J Med Ethics* 2008; 34(4):308-314.
- w31. Tully J, Ninis N, Booy R, Viner R. The new system of review by multicentre research ethics committees: prospective study. *BMJ* 2000; 320(7243):1179-1182.
- w32. Angell E, Sutton AJ, Windridge K, Dixon-Woods M. Consistency in decision making by research ethics committees: a controlled comparison. *J Med Ethics* 2006; 32(11):662-664.
- w33. Angell EL, Jackson CJ, Ashcroft RE, Bryman A, Windridge K, Dixon-Woods M. Is 'inconsistency' in research ethics committee decision-making really a problem? An empirical investigation and reflection. *Clinical Ethics* 2007; 2(2):92-99.
- w34. Dziak K, Anderson R, Sevick MA, Weisman CS, Levine DW, Scholle SH. Variations among Institutional Review Board reviews in a multisite health services research study. *Health Serv Res* 2005; 40(1):279-290.
- w35. Petersen LA, Simpson K, Sorelle R, Urech T, Chitwood SS. How variability in the institutional review board review process affects minimal-risk multisite health services research. *Ann Intern Med* 2012; 156(10):728-735.
- w36. Stair TO, Reed CR, Radeos MS, Koski G, Camargo CA. Variation in institutional review board responses to a standard protocol for a multicenter clinical trial. *Acad Emerg Med* 2001; 8(6):636-641.
- w37. Silverman H, Hull SC, Sugarman J. Variability among institutional review boards' decisions within the context of a multicenter trial. *Crit Care Med* 2001; 29(2):235-241.
- w38. Roberts LM, Bowyer L, Homer CS, Brown MA. Multicentre research: negotiating the ethics approval obstacle course. *Med J Aust* 2004; 180(3):139.
- w39. Sansone RA, McDonald S, Hanley P, Sellbom M, Gaither GA. The stipulations of one institutional review board: a five year review. *J Med Ethics* 2004; 30(3):308-310.
- w40. Larson E, Bratts T, Zwanziger J, Stone P. A survey of IRB process in 68 U.S. hospitals. *Journal of Nursing Scholarship* 2004; 36(3):260-264.
- w41. Al-Shahi R, Warlow C. Using patient-identifiable data for observational research and audit. *BMJ* 2000; 321(7268):1031-1032.
- w42. Willison DJ. Data protection and the promotion of health research: if the laws are not the problem, then what is? *Health Policy* 2007; 2(3):39-43.
- w43. Kolman JM, Wray NP, Ashton CM, Wenner DM, Jarman AF, Brody BA. Conflicts among multinational ethical and scientific standards for clinical trials of therapeutic interventions. *J Law Med Ethics* 2012; 40(1):99-121.
- w44. Armitage J, Souhami R, Friedman L, Hilbrich L, Holland J, Muhlbaier LH et al. The impact of privacy and confidentiality laws on the conduct of clinical trials. *Clin Trials* 2008; 5(1):70-74.
- w45. Emanuel EJ. Reconsidering the Declaration of Helsinki. *Lancet* 2013; 381(9877):1532-1533.
- w46. Angell E, Dixon-Woods M. Do research ethics committees identify process errors in applications for ethical approval? *J Med Ethics* 2009; 35(2):130-132.

Figure

- w47. Black M, Leese B, Gosden T. Local research ethics committees. Differences in application process cause problems. *BMJ* 1995; 311(7019):1572.
- w48. Garfield P. Cross district comparison of applications to research ethics committees. *BMJ* 1995; 311(7006):660-661.
- w49. Ahmed AH, Nicholson KG. Delays and diversity in the practice of local research ethics committees. *J Med Ethics* 1996; 22(5):263-266.
- w50. Redshaw ME, Harris A, Baum JD. Research ethics committee audit: differences between committees. *J Med Ethics* 1996; 22(2):78-82.
- w51. Ah-See KW, MacKenzie J, Thakker NS, Maran AG. Local research ethics committee approval for a national study in Scotland. *J R Coll Surg Edinb* 1998; 43(5):303-305.
- w52. Al-Shahi R, Warlow CP. Ethical review of a multicentre study in Scotland: a weighty problem. *J R Coll Physicians Lond* 1999; 33(6):549-552.

- w53. Maskell NA, Jones EL, Davies RJ. Variations in experience in obtaining local ethical approval for participation in a multi-centre study. *QJM* 2003; 96(4):305-307.
- w54. Sarson-Lawrence M, Alt C, Mok MT, Dodds M, Rosenthal MA. Trust and confidence: towards mutual acceptance of ethics committee approval of multicentre studies. *Intern Med J* 2004; 34(11):598-603.
- w55. Dziak K, Anderson R, Sevick MA, Weisman CS, Levine DW, Scholle SH. Variations among Institutional Review Board reviews in a multisite health services research study. *Health Serv Res* 2005; 40(1):279-290.
- w56. Lambers Heerspink HJ, Dobre D, Hillege HL, Grobbee DE, de ZD. Does the European clinical trials directive really improve clinical trial approval time? *Br J Clin Pharmacol* 2008; 66(4):546-550.
- w57. Geldenhuys H, Veldsman A, Tameris M, Luabeya A, Hanekom W, Mahomed H et al. Analysis of time to regulatory and ethical approval of SATVI TB vaccine trials in South Africa. *S Afr Med J* 2013; 103(2):85-89.
- w58. Dumville JC, Watson J, Raynor P, Torgerson DJ. Research Governance: a barrier to ethical research? *QJM* 2004; 97(3):113-114.
- w59. Elwyn G, Seagrove A, Thorne K, Cheung WY. Ethics and research governance in a multicentre study: add 150 days to your study protocol. *BMJ* 2005; 330(7495):847.
- w60. Al-Shahi Salman R, Brock TM, Dennis MS, Sandercock PA, White PM, Warlow C. Research governance impediments to clinical trials: a retrospective survey. *J R Soc Med* 2007; 100(2):101-104.
- w61. Kielmann T, Tierney A, Porteous R, Huby G, Sheikh A, Pinnock H. The Department of Health's research governance framework remains an impediment to multi-centre studies: findings from a national descriptive study. *J R Soc Med* 2007; 100(5):234-238.
- w62. Vajdic CM, Meagher NS, Hicks SC, Faedo M, Ward RL, Pearson SA. Governance approval for multisite, non-interventional research: what can Harmonisation of Multi-Centre Ethical Review learn from the New South Wales experience? *Intern Med J* 2012; 42(2):127-131.
- w63. Mallick AA, O'Callaghan FJ. Research governance delays for a multicentre non-interventional study. *J R Soc Med* 2009; 102(5):195-198.

Disproportionate regulation

- w64. Hemminki E, Veerus P, Virtanen J, Lehto J. A qualitative study on clinical research in Finland: fragmented governance and volume in the 2000s. *BMJ Open* 2013; 3(2).
- w65. Hemminki E, Virtanen J, Veerus P, Regushevskaya E. Clinical research in Finland in 2002 and 2007: quantity and type. *Health Res Policy Syst* 2013; 11:17.
- w66. Hartmann M. Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries. *Trials* 2012; 13:53.
- w67. Keim B. Tied up in red tape, European trials shut down. *Nat Med* 2007; 13(2):110.
- w68. Berendt L, Hakansson C, Bach KF, Dalhoff K, Andreassen PB, Petersen LG et al. Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006. *BMJ* 2008; 336(7634):33-35.
- w69. Thompson M, Heneghan C, Billingsley M, Cohen D. Medical device recalls and transparency in the UK. *BMJ* 2011; 342:d2973.

Management of clinical biomedical research

- w70. Lienard JL, Quinaux E, Fabre-Guillevin E, Piedbois P, Jouhaud A, Decoster G et al. Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer. *Clin Trials* 2006; 3(5):486-492.
- w71. Pronker E, Geerts BF, Cohen A, Pieterse H. Improving the quality of drug research or simply increasing its cost? An evidence-based study of the cost for data monitoring in clinical trials. *Br J Clin Pharmacol* 2011; 71(3):467-470.
- w72. Tolmie EP, Dinnett EM, Ronald ES, Gaw A. Clinical Trials: Minimising source data queries to streamline endpoint adjudication in a large multi-national trial. *Trials* 2011; 12:112.

Recommendations

Recommendation 2

- w73. Chakladar A, Eckstein S, White SM. Paper use in research ethics applications and study conduct. *Clin Med* 2011; 11(1):44-47.
- w74. Sustainable Trials Study Group. Towards sustainable clinical trials. *BMJ* 2007; 334(7595):671-673.
- w75. Sackett DL. Six pairs of things to celebrate on International Clinical Trials Day. *Trials* 2013; 14(1):128.

- w76. De Feo G, Chiabrando G, Cannovo N, Galluccio A, Tomino C. Harmonization of the practice of independent ethics committees in Italy: project E-submission. PLoS ONE 2012; 7(11):e48906.
- w77. De Feo G, Signoriello S, Bryce JC, Del GA, Canzanella G, Crudele F et al. Time spent for activation of non-profit studies in oncology in Italy. PLoS ONE 2010; 5(7):e11864.
- w78. Savulescu J. Harm, ethics committees and the gene therapy death. J Med Ethics 2001; 27(3):148-150.
- w79. Savulescu J, Spriggs M. The hexamethonium asthma study and the death of a normal volunteer in research. J Med Ethics 2002; 28(1):3-4.
- w80. Savulescu J. Two deaths and two lessons: is it time to review the structure and function of research ethics committees? J Med Ethics 2002; 28(1):1-2.

Recommendation 3

- w81. Leonard JC, Scharff DP, Koors V, Lerner EB, Adalgais KM, Anders J et al. A qualitative assessment of factors that influence emergency medical services partnerships in prehospital research. Acad Emerg Med 2012; 19(2):161-173.
- w82. Bakken S, Lantigua RA, Busacca LV, Bigger JT. Barriers, enablers, and incentives for research participation: a report from the Ambulatory Care Research Network (ACRN). J Am Board Fam Med 2009; 22(4):436-445.
- w83. Ennis L, Wykes T. Impact of patient involvement in mental health research: longitudinal study. Br J Psychiatry 2013;203:381-6
- w84. Moss AJ, Francis CW, Ryan D. Collaborative clinical trials. N Engl J Med 2011; 364(9):789-791.
- w85. Tognoni G, Franzosi MG, Garattini S, Maggioni A, Lotto A, Mauri F et al. The case of GISSI in changing the attitudes and practice of Italian cardiologists. Stat Med 1990; 9(1-2):17-26.
- w86. Tognoni G, Fresco C, Maggioni AP, Turazza FM. The GISSI Story (1983-1996): A Comprehensive Review. Journal of Interventional Cardiology 1997; 10(1):3-28.
- w87. IOM (Institute of Medicine). Large simple trials and knowledge generation in a learning health system: Workshop summary. 2013. Washington, DC: The National Academies Press.

Recommendation 4

- w88. Stead M, Cameron D, Lester N, Parmar M, Haward R, Kaplan R et al. Strengthening clinical cancer research in the United Kingdom. Br J Cancer 2011; 104(10):1529-1534.
- w89. Hagen NA, Stiles CR, Biondo PD, Cummings GG, Fainsinger RL, Moulin DE et al. Establishing a multicentre clinical research network: lessons learned. Curr Oncol 2011; 18(5):e243-e249.
- w90. Tierney WM, Oppenheimer CC, Hudson BL, Benz J, Finn A, Hickner JM et al. A national survey of primary care practice-based research networks. Ann Fam Med 2007; 5(3):242-250.
- w91. Werner JJ. Measuring the impact of practice-based research networks (PBRNs). J Am Board Fam Med 2012; 25(5):557-559.